{
    "eid": "2-s2.0-85123646568",
    "title": "What is the best systemic treatment for newly diagnosed inflammatory breast cancer?-a narrative review",
    "cover-date": "2021-12-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Oncology",
            "@code": "2730",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "anti-HER2 therapy",
        "CDK4/6 inhibitor",
        "immunotherapy",
        "Inflammatory breast cancer (IBC)"
    ],
    "authors": [
        "Sudpreeda Chainitikun",
        "Siyamol Mingmalairak",
        "Napa Parinyanitikul"
    ],
    "citedby-count": 2,
    "ref-count": 38,
    "ref-list": [
        "Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer",
        "Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis",
        "Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study",
        "Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy",
        "Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer",
        "Inflammatory breast cancer: early recognition and diagnosis is critical",
        "Inflammatory carcinomas of the breast: a clinical, pathological, or a clinical and pathological definition?",
        "Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer",
        "Inflammatory breast cancer biology: the tumour microenvironment is key",
        "Biomarkers for Inflammatory Breast Cancer: Diagnostic and Therapeutic Utility",
        "Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations",
        "Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer",
        "Identification of frequent somatic mutations in inflammatory breast cancer",
        "International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference",
        "Inflammatory Breast Cancer: A Literature Review",
        "Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)",
        "Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study",
        "Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial",
        "NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC)",
        "Pembrolizumab for Early Triple-Negative Breast Cancer",
        "Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial",
        "Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial",
        "Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC)",
        "Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial",
        "Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer",
        "PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy",
        "Infiltrating stromal immune cells in inflammatory breast cancer are associated with an improved outcome and increased PD-L1 expression",
        "The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome",
        "Update on systemic treatment for newly diagnosed inflammatory breast cancer",
        "Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)",
        "Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer",
        "Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study",
        "Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial",
        "Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer",
        "Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial",
        "Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer",
        "Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60022183",
            "affilname": "King Chulalongkorn Memorial Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022183",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "125374400",
            "affilname": "MedPark Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/125374400",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}